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ABSTRACT 
Background: Structural cortical networks (SCNs) represent patterns of coordinated morphological 
modifications in cortical areas and they present the advantage of being extracted from previously 
acquired clinical MRI scans. SCNs have shown pathophysiological changes in many brain 
disorders, including multiple sclerosis. 
Objective: To investigate alterations of SCNs at the individual level in patients with clinically 
isolated syndrome (CIS), thereby assessing their clinical relevance. 
Methods: We analyzed baseline data collected in a prospective multi-center (MAGNIMS) study. 
CIS patients (n=60) and healthy controls (n=38) underwent high resolution 3T MRI. Measures of 
disability and cognitive processing were obtained for patients. Single-subject structural cortical 
networks were extracted from brain 3D-T1 weighted sequences; global and local network 
parameters were computed.  
Results: Compared to healthy controls, CIS patients showed altered small-world topology, an 
efficient network organization combining dense local clustering with relatively few long-distance 
connections. These disruptions were worse for patients with higher lesion load and worse cognitive 
processing speed. Alterations of centrality measures and clustering of connections were observed in 
specific cortical areas in CIS patients when compared with healthy controls.  
Conclusion: Our study indicates that SCNs can be used to demonstrate clinically relevant alterations 
of connectivity in clinically isolated syndrome. 
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INTRODUCTION  
Multiple sclerosis (MS) is a chronic inflammatory demyelinating and degenerative disease of the 
central nervous system. For most patients, MS starts with an acute neurological episode known as a 
clinically isolated syndrome (CIS)1. Conventional MRI findings are the best predictors of 
conversion to MS, although measures such as the WM lesion volume only partially correlate with 
the variable course of the disease2. MRI abnormalities in the normal-appearing white and gray 
matter, and connectivity alterations may contribute to clinical outcome of patients with CIS3.  
Functional changes in the brain can lead to related morphological modification in cortical areas4,5 
and, recently, it has become possible to describe these coordinated patterns of cortical morphology 
with network parameters6. In structural cortical networks (SCNs), the nodes correspond to cortical 
areas considered connected by edges when they have structural similarity in thickness or volume 
across subjects7 or within single subjects8. In comparison with other brain graphs (e.g., structural 
graphs derived from diffusion tensor imaging or functional graphs derived from synchronic 
activation of brain areas), SCNs present the unique advantage of being derived from anatomical 
MRI acquisitions, such as a 3D T1-weighted sequence, frequently available in acquired datasets and 
even in routine clinical protocols.  
SCNs have shown clinically relevant changes in many brain diseases9–11. However, few studies so 
far have investigated SCNs in multiple sclerosis (MS)12–15.  
SCN analysis has revealed in MS patients a disruption of physiological small-world network 
topology of the brain: an efficient organization, shared by most of the complex systems in nature, 
including brain networks, that is neither completely regular nor completely random, because it 
combines a dense local clustering with relatively few long-distance connections16. Whilst MS 
patients can shift in either direction, either a more regular13,14  or a more random network12,15, the 
only study including a small cohort of CIS patients14 demonstrated an increased clustered 
organization of SCNs in CIS subjects compared with healthy controls (HCs). Regular networks, 
such as lattices, are highly clustered, but with a long path length: nodes are densely connected with 
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their clique of neighbors, whereas they are linked to distant nodes only through several intermediate 
steps, causing a decrease in the global network efficiency. However, the SCNs were extracted at 
group level in the CIS cohort, and so it remains unclear whether and how these disruptions are 
associated with individual measures of disability.  
Our aim was to investigate SCNs alterations in a larger CIS patient cohort by constructing the 
network at the individual level, thereby assessing the clinical relevance of the SCN alterations. 
Moreover, since SCNs have been studied exclusively in single-center studies before, our secondary 
aim was to evaluate the impact of across-scanner variations on single-subject SCNs analysis. 
 
MATERIALS AND METHODS 
Participants 
This study represents a re-analysis of the baseline data which were acquired as part of a prospective 
MAGNIMS (www.magnims.eu) 3-year multi-center, multi-vendor project, conducted at the 
following six MS Centers (Table 1). Previous studies using the same cohort addressed a different 
issue and are unrelated to this analysis17,18. 
Sixty patients experiencing symptoms suggestive of a CIS (age 18 to 59 years at baseline) were 
recruited from the six participating centers within six months of symptom onset.  Thirty-eight age 
and gender-matched healthy controls (HCs) were also recruited (Table 1). Exclusion criteria for all 
participants were a history of other known medical conditions that could have affected the brain 
(vascular, malignant, neurological) and MRI related contra-indications.  
Clinical examination  
At baseline, CIS patients underwent neurological examination and Expanded Disability Status Scale 
(EDSS) was assessed by a trained physician. Forty-seven patients were also tested for information 
processing speed with the Symbol Digit Modality Test (SDMT). 
Image acquisition and post-processing 
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All subjects underwent a baseline MRI scan of the brain and spinal cord at a 3T scanner, and CIS 
patients additionally underwent administration of intravenous contrast. The scanning parameters 
were based on local protocols and followed the MAGNIMS guidelines19. The acquisition protocols 
for the different vendors has been previously described18: it included  brain 3D T1-weighted (1mm 
isotropic) and 3D fluid-attenuated inversion recovery (FLAIR); proton density/T2 and post-contrast 
T1-weighted sequences for brain and spinal cord.  
White matter lesion number and location (periventricular, juxtacortical, deep WM, infratentorial 
and spinal) were recorded. Subsequently, dissemination in space and time, as well as MS diagnosis, 
were determined according to the revised 2017 McDonald criteria20. 
White matter lesion segmentation was performed with a semi-automated process using the 3D 
FLAIR and 3D T1-weighted MRI sequences21 All lesion masks were checked, corrected manually 
and lesion volumes subsequently obtained. These lesion masks were registered to the 3D T1-
weighted sequence and the registered T1 lesion masks were used for lesion filling22, after which 
cortical gray matter (CGM) was automatically segmented and parcellated using GIF23.  All 
segmentations were quality checked. Ninety-eight cortical areas were identified in the native-space 
bilateral CGM according to the Desikan-Killiany-Tourville protocol 
(http://braincolor.mindboggle.info)24. 
For computational reasons, CGM segmentation on the 3D T1-weighted images was resliced to 2.0 
mm isotropic voxels to reduce the dimensionality of the data8.  
Single-subject gray matter graphs 
SCNs were extracted at subject level using software developed by T.B.M 
(https://github.com/bettytijms/Single_Subject_Grey_Matter_Networks) in Matlab v7.12.0.635.  
Briefly, first, the SCNs’ nodes were defined as regions-of-interest in the native space CGM 
segmentation, corresponding to 3x3x3 voxel cubes. This was chosen because a 3-voxel size can 
capture the thickness and folding of the cortex25 without generating large matrices of cubes.    
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The similarity between all the cubes (nodes) in the network was determined with the correlation 
coefficient, which was collected in a matrix that was subsequently thresholded and binarized, so 
that the chance of having spurious correlations for all single-subject SCNs was < or = to 5%. The 
obtained graphs were undirected with nodes connected each other by edges, only if their similarity 
matrix survived this threshold (Figure 1).  
Graph properties 
First, we determined the following global graph-defining properties: the size of the SCNs (i.e., the 
number of cubes), the average degree (i.e., the number of edges) and the connectivity density (i.e., 
the proportion of existing connections to the maximum number of possible connections). Then, we 
computed the global graph parameters averaged across all cubes: the characteristic path length26, 
the clustering coefficient16, the betweenness centrality27 and the eigenvector centrality28. In 
addition, the clustering coefficient and characteristic path length of each graph were normalised 
with those of 20 randomised reference graphs of identical size and degree distribution8. The small-
world coefficient was then obtained from the ratio between the normalised clustering coefficient () 
and the normalised characteristic path length (). A network shows a small-world properties when 
its nodes are highly clustered, as in regular lattices, but they can also be reached from every other 
node in a small number of steps, e.g. in random graphs, resulting in a ratio between  and  greater 
than 129. 
At regional level, we averaged the local graph parameters across the nodes within each of the 98 
cortical areas, which had been parcellated with GIF in each individual subject, in order to reduce 
the dimensionality of the SCNs and increase the comparability between subjects, across centers and 
possibly with previous studies30. 
Statistical analysis  
Group differences in demographic characteristics and CGM volume were assessed using two-
sample t-tests for continuous variables and chi-square tests for categorical variables.  
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We initially applied a multivariate linear regression model to compare graph properties between 
groups adjusting for age and gender and CGM volume. Since non-normalised global graph 
parameters (betweenness centrality, eigenvector centrality, clustering coefficient and path length) 
are dependent on graph-defining properties (size, connectivity density and degree), we included any 
of these graph-defining properties when they were significantly different between groups as 
additional independent variables to the model. We tested possible nonlinear effects of age with 
quadratic regression analysis imputing graph parameters as dependent variables.  
Since the analysis of the global graph parameters was meant to be exploratory, we did not perform 
multiple comparison adjustments. 
Group differences in local graph parameters in the 98 CGM areas were assessed with linear 
regression, correcting for age, gender and local CGM volume). Due to concerns about residual 
variance heterogeneity across centers, the regression was estimated using the Hubert-White31,32 
standard error, which is known to be robust to residual heterogeneity. Significant P values were  
identified correcting for multiple comparisons using a False Discovery Rate (FDR) of 5% for 
multiple hypothesis testing33.   
WM lesion volumes were log transformed to allow parametric testing34 and the relationships 
between these and global/local graph metrics as well as clinical parameters (EDSS, SDMT, MS 
diagnosis according to the 2017 McDonald criteria) were assessed using linear regression adjusting 
for age and gender. Associations between local/global graph metrics changes and clinical 
parameters were assessed with linear regression adjusting for age and gender. The WM lesion 
volume was included as an additional independent variable to the model if associated with the 
clinical parameters. 
Since CIS patients are heterogeneous in terms of the number of WM lesions, an established risk 
factor for conversion to MS, we also divided patients into distinct groups according to the number 
of intracranial WM lesions: 0-1, 2-9 and >10 lesions (Table 1). This allowed further comparisons 
between HCs and patients at different risk stage of developing MS35.  
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Not all centers provided both HCs and patients, hence we investigated and controlled for center 
effects in the following manner. In addition to entering the center as a covariate in a linear 
regression including all centers, with graph metrics as dependent variables and age, gender and 
CGM volume as the other covariates, we performed a further analysis restricted to those centers 
contributing both patients and HCs (Basel, Bochum and London).  If the between-group graph 
parameter differences or p-values were materially altered by inclusion of center in either the full or 
the restricted analyses, center was retained as covariate in the unrestricted model over all centers. 
Statistical analyses were performed with Stata v. 14.1 (Stata Corporation, College Station, Texas, 
USA). 
 
RESULTS 
Subject Characteristics 
The clinical and radiological characteristics of the participants (60 patients and 38 healthy controls) 
are provided in Table 1. CIS patients and HCs did not show significant differences in age, gender 
and CGM volumes. CIS patients had low disability and were cognitively preserved. Out of the 
entire sample of 60 patients, eight fulfilled the 2017 McDonald criteria for MS.  
Participants’ characteristics across centers are detailed in eTable1 in Supporting Information. 
Global graph metrics 
All single-subject SCNs did not exhibit disconnected nodes.  
Both CIS and HC groups retained small-world topology (/>1), but in CIS patients the 
multivariate regression analysis (R2=0.06, F(4, 92)=2.38, p<0.05) showed  a higher  than HCs (B= 
0.01, 95% CIs=0.003-0.02, p=0.012) . CIS patients showed also (R2=0.11, F(4, 92)=3.41, p<0.05)  a 
higher small-world coefficient than HCs (B= 0.01, 95% CIs=0.004-0.02, p=0.003).  
Age and age squared did not have any effects on the global graph metrics. 
After correction for center effect, the differences between CIS patients and HCs for small-world 
coefficient remained significant (p=0.024) but not for  (Table 2). 
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Center/scanner effect was also significant for connectivity density (p<0.0001) and for all global 
graph parameters (p<0.0001). Therefore, center was retained as covariate in the multivariate 
regression analysis. See eTable2 in Supplemental Material for the SCNs parameters across centers. 
For global graph-defining properties, CIS patients had smaller network sizes compared with HCs 
(Table 2); therefore, in order to compare SCNs between CIS and HC groups, we adjusted the 
analysis of the non-normalised global graph parameters for the network size. CIS patients initially 
showed higher eigenvector centrality than controls (B=0.07, 95% CIs=0.01-0.1, p=0.02), but this 
difference lost significance after adjusting for network size (Table 2). 
In CIS patients, a higher small-world coefficient was associated (R2=0.17, F(3, 55)=3.64, p<0.05) 
with higher WM lesion volume (= 0.36, p=0.007), after adjusting for age (= 0.03, p=0.832) and 
gender (= -0.18, p=0.162); additionally, CIS patients with higher lesion counts (>10 lesions) 
showed higher gamma and greater small-world coefficients compared with HCs and with CIS 
patients with lower lesion numbers (Figure 2). The small-world coefficient in CIS patients and the 
WM lesion location were not significantly associated. 
Amongst the 47 CIS patients with SDMT scores available, a higher small-world coefficient was 
associated (R2=0.21,F(3,43)=3.86, p<0.05) with a lower SDMT score (i.e. slower information 
processing speed) (= -0.39, p=0.008) after adjusting for  age (= -0.81, p=0.42) and gender (= 
0.85, p=0.4)  (Figure 3). There were too few MS patients (n=9) in our cohort to allow comparisons 
with HCs and other CIS patients not diagnosed with MS. 
Local graph metrics 
We investigated whether differences between CIS patients and HCs were specific to particular 
cortical areas. Patients and controls showed similar volumes in the 98 CGM areas and there were no 
significant differences in degree. Several cortical areas showed significant differences for 
betweenness centrality, clustering coefficient and path length (p<0.05), but only three survived 
correction for multiple testing (see eTable3 in Supplemental Material). Patients showed lower 
betweenness centrality in the right superior frontal gyrus (0.300.01 vs 0.330.01, p<0.0001; 
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pFDR<0.05) and lower clustering coefficient in the right postcentral gyrus (0.510.04 vs 0.540.03, 
p<0.0001; pFDR<0.05) in comparison to HCs (Figure 4).  Among CIS patients, these alterations 
were not correlated with clinical parameters or WM lesion volume.  
Finally, CIS patients with >10 WM lesions had lower betweenness centrality in the right postcentral 
gyrus (0.290.01 0.330.01, pFDR<0.05) and lower clustering coefficient in the right medial orbital 
gyrus (0.510.04 vs 0.530.03, pFDR<0.05), compared with HCs.  
There was significant (pFDR<0.05) variability across centers in the following local graph properties: 
characteristic path length in the bilateral anterior insula, left inferior and middle temporal gyrus, left 
parahippocampal gyrus; clustering coefficient in the right inferior and middle occipital gyrus; 
betweenness centrality in the left posterior cingulate cortex and eigenvector centrality in the right 
middle occipital gyrus.  
 
DISCUSSION 
In this study, using single-subject SCN analysis, we showed that in CIS patients, graph alterations 
are related to disease burden. At the global level, CIS patients possess altered small-world topology 
characterized by a shift towards a more regular network. These findings are in line with previous 
studies on SCNs in CIS patients14.  A regular network tends to possess dense local connections (i.e. 
high clustering) between nodes at the expenses of the long-distance ones (i.e. low path length), thus 
compromising the efficient balance between short and long-range information transfer, distinctive 
of small-world  networks16.   
 When comparing the whole CIS cohort with HCs, the difference in small-world coefficient was 
significant, but small. This small difference could be because CIS patients were at the very onset of 
the disease, some of them with little WM damage. When patients were stratified according to the 
number of WM lesions, this difference in the small-world coefficient increased: subjects with 
higher lesion load at onset showed higher small-world coefficient values compared not only with 
HCs, but also with the group of CIS patients with 0-1 lesion.  
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This altered topology was correlated with a high lesion load. Moreover, we did not find any 
significant differences in cortical volumes between groups: in CIS patients the tendency to lose 
long-distance connections could be a consequence of altered connectivity due to lesional disruption 
of WM tracts more than to alterations in cortical areas.  
The increase in the small-world coefficient, in our study, was associated with worse cognitive 
performance. Noteworthy, the analysis of single-subject SCNs in established MS15, similar to 
studies conducted with the same methodology in dementia10, showed that cognitively impaired 
patients tend to possess random SCN topology. However, unlike individuals in our cohort, those 
patients already had evidence of definite gray matter atrophy. This suggests that small-world 
topology alterations of the SCNs may have different characteristics at different stages of the 
disease, being more regular in the early phases and more random when neurodegeneration starts to 
occur.   
At local level, CIS patients had altered network properties in several cortical region, including low 
clustering coefficient in areas relevant to cognition. These alterations do not seem to affect the 
global SCNs properties and the clinical phenotype. However, studies with further cognitive 
assessments and longitudinal follow-up could investigate the clinical relevance of these findings. 
In our study, SCNs differed in size between CIS patients and HCs, although the two groups did not 
show any difference in CGM volume. It is possible that the smaller size of patients’ SCNs could 
result from the different MRI pre-processing, particularly the WM lesion segmentation in patients, 
or from the presence of intra-cortical lesions. Most studies use methods that constrain networks into 
identical sizes (i.e. parcellated cortical areas), whereas, here, we chose to extract SCNs from native 
space segmentations, thus preserving the inter-individual variability.  However, it is still not clear 
how to compare graphs with different sizes and/or connectivity densities30. Here, we adjusted for 
SCN size in our statistical models, but after this, we could not detect any differences in non-
normalised global graph-parameters between CIS patients and HCs. 
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One final consideration is the multi-center setting of our study giving rise to inter-center variability. 
Inter-scanner variations had significant effects on the global graph parameters. This may have been 
due to differences in WM-GM interface contrast across different scanners that influenced the CGM 
segmentation outcomes. Our findings suggest that it is important to account for inter-center 
variability for single-subject SCN extraction from multi-center neuroimaging datasets. The 
advantage of multi-center settings though is the putative increase in statistical power and, although 
variance heterogeneity across centers may be a potential problem for our analysis, the relative 
robustness of the small-world result suggests this may not in our case be a major limitation. 
 
CONCLUSIONS 
In this study, we applied, for the first time, a recently developed method to extract single-subject 
SCNs in CIS. Using clinical scans, we were able to demonstrate altered small-world topology in 
CIS patients SCNs that was associated with cognitive processing. This suggests that SCNs are 
affected early in MS and can represent a potential biomarker. Future longitudinal analyses will 
assess if the observed changes in SCNs can predict conversion to MS during the follow-up. 
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